{"groups":[{"description":"* Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.\n* Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.\n* Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.","id":"FG000","title":"Cisplatin, C225, Radiation"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Not started protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"other reason"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"69"}],"type":"STARTED"},{"achievements":[{"comment":"3 patients never started treatment","groupId":"FG000","numSubjects":"66"}],"type":"Began Protocol Therapy"},{"achievements":[{"comment":"6 treated patients were ineligible","groupId":"FG000","numSubjects":"60"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was open to accrual on 12/21/2004, accrued its first patient on April 8, 2005, and was closed on 07/20/2006. The final accrual was 69 patients."}